Login

Switch On Your HIV Smarts.

AIDS 2012: Your Day-Two Dose of Science

AIDS 2012: Your Day-Two Dose of Science

, by Reilly O'Neal

As day two of AIDS 2012 winds down, here's a quick hit of science around black gay men's health and treatment as prevention. Read More

Dolutegravir Looks Good in Another Advanced Clinical Trial

Dolutegravir Looks Good in Another Advanced Clinical Trial

, by Reilly O'Neal

Learn more about this next-generation integrase inhibitor and see how it stacks up against popular HIV drug regimen Atripla. Read More

Reducing Inflammation: Do Some HIV Drugs Work Better Than Others?

Reducing Inflammation: Do Some HIV Drugs Work Better Than Others?

, by San Francisco AIDS Foundation

New research suggests starting antiretroviral treatment reduces inflammation caused by HIV infection—but plenty of questions remain. Read More

Ask a Guinea Pig: What Do I Need to Know Before Joining a PrEP Trial?

Ask a Guinea Pig: What Do I Need to Know Before Joining a PrEP Trial?

, by Matt Sharp

BETA's new column shares an insider perspective on taking part in clinical trials. Thinking of joining a study of PrEP—a pill a day for HIV prevention? Start here. Read More

New HIV Drugs on the Way?

New HIV Drugs on the Way?

, by San Francisco AIDS Foundation

New HIV treatment options may be available by late summer. HIVandHepatitis.com's Liz HIghleyman gives the scoop on elvitegravir, cobicistat, and the "Quad" pill. Read More